Literature DB >> 9717968

Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

L Biancone1, G Monteleone, R Marasco, F Pallone.   

Abstract

Autoimmunity to cytoskeletal protein tropomyosin (TM) has been demonstrated in UC. However, the TM isoforms involved in this IgG-mediated autoimmune response in UC and the possible presence of serum IgG antibodies against TM (hTMs IgG) in unaffected UC relatives are unknown. The aim of this study was to investigate the human TM (hTM) isoforms recognized by serum IgG from UC and to explore whether hTM IgG antibodies are present in healthy UC relatives. We studied 33 UC patients with 58 unaffected relatives, 31 Crohn's disease (CD) patients with 31 unaffected relatives and 20 controls (C). Serum IgG against four recombinant hTM isoforms (hTM1, 2, 3, 5) were tested by ELISA. p-ANCA were tested by ELISA and immunofluorescence. Serum hTM1 and hTM5 IgG were higher in UC patients than in CD and C (P<0.005). Among UC patients 52% were seropositive for hTM1 and 64% for hTM5 (P<0.001 versus CD and C). In UC, hTM5 IgG were higher in p-ANCA+ than in ANCA- patients (P=0.04). In UC relatives hTM1 IgG were higher than in CD relatives and C (P<0.01). UC relatives were more frequently seropositive for hTM1 than hTM5 IgG (P=0.001). while probands were more frequently seropositive for hTM5 IgG (P=0.008). We conclude that autoimmunity to hTMI and hTM5 is a feature of UC, while hTM1 IgG differentiate UC relatives from controls. A genetic susceptibility to immune recognition of hTM isoforms in UC is suggested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717968      PMCID: PMC1905040          DOI: 10.1046/j.1365-2249.1998.00610.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  The molecular basis for tropomyosin isoform diversity.

Authors:  J P Lees-Miller; D M Helfman
Journal:  Bioessays       Date:  1991-09       Impact factor: 4.345

2.  Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

3.  Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway.

Authors:  M Donowitz
Journal:  Gastroenterology       Date:  1985-02       Impact factor: 22.682

4.  Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

Authors:  J Satsangi; K I Welsh; M Bunce; C Julier; J M Farrant; J I Bell; D P Jewell
Journal:  Lancet       Date:  1996-05-04       Impact factor: 79.321

5.  Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis.

Authors:  L Biancone; A Mandal; H Yang; T Dasgupta; A O Paoluzi; A Marcheggiano; P Paoluzi; F Pallone; K M Das
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

6.  Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis.

Authors:  F Seibold; D Slametschka; M Gregor; P Weber
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

7.  Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components.

Authors:  G M Hänsch; M Seitz; G Martinotti; M Betz; E W Rauterberg; D Gemsa
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

8.  Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence.

Authors:  T S Halstensen; T E Mollnes; P Brandtzaeg
Journal:  Gastroenterology       Date:  1989-07       Impact factor: 22.682

9.  Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup.

Authors:  R H Duerr; D A Neigut
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

10.  Human fibroblast tropomyosin isoforms: characterization of cDNA clones and analysis of tropomyosin isoform expression in human tissues and in normal and transformed cells.

Authors:  R E Novy; J L Lin; C S Lin; J J Lin
Journal:  Cell Motil Cytoskeleton       Date:  1993
View more
  10 in total

Review 1.  Vertebrate tropomyosin: distribution, properties and function.

Authors:  S V Perry
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

2.  Alpha tropomyosin as a self-antigen in patients with Behçet's disease.

Authors:  S P Mahesh; Zhuqing Li; R Buggage; F Mor; I R Cohen; E Y Chew; R B Nussenblatt
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 3.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 4.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

5.  Externalization of tropomyosin isoform 5 in colon epithelial cells.

Authors:  K V Kesari; N Yoshizaki; X Geng; J J Lin; K M Das
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  Autoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5.

Authors:  E K Onuma; P S Amenta; K Ramaswamy; J J Lin; K M Das
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

7.  Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells.

Authors:  S Sakamaki; N Takayanagi; N Yoshizaki; S Hayashi; T Takayama; J Kato; K Kogawa; N Yamauchi; N Takemoto; A Nobuoka; T Ayabe; Y Kohgo; Y Niitsu
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

8.  Proinflammatory progranulin antibodies in inflammatory bowel diseases.

Authors:  Lorenz Thurner; Elisabeth Stöger; Natalie Fadle; Philipp Klemm; Evi Regitz; Maria Kemele; Birgit Bette; Gerhard Held; Marc Dauer; Frank Lammert; Klaus-Dieter Preuss; Vincent Zimmer; Michael Pfreundschuh
Journal:  Dig Dis Sci       Date:  2014-03-04       Impact factor: 3.199

Review 9.  Coherent somatic mutation in autoimmune disease.

Authors:  Kenneth Andrew Ross
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

10.  Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease.

Authors:  Yin Zhang; Heru Zhao; Bin Liu; Li Li; Lulu Zhang; Mei Bao; Xinyu Ji; Xiaojuan He; Jianfeng Yi; Peng Chen; Cheng Lu; Aiping Lu
Journal:  Front Pharmacol       Date:  2020-02-27       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.